The authors have no conflicts of interest, financial or otherwise, to disclose. Selected abbreviations and acronyms BDNF brain-derived neurotrophic factor CREB cAMP response element binding ERK extracellular signal-related kinase MAPK mitogen activated protein kinase NAA N-acetyl aspartate P13K FI3-kinase Wnt/GSK wingless/glycogen synthase kinase Contributor Information Joshua Hunsberger, Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Program, NIMH, NIH, Bethesda, Maryland, USA. Daniel R.

Austin, Laboratory of Molecular Pathophysiology and Experimental #17-AAG HSP inhibitor keyword# Therapeutics, Mood and Anxiety Disorders Program, NIMH, NIH, Bethesda, Inhibitors,research,lifescience,medical Maryland, USA. Ioline D. Henter, Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Program, NIMH, NIH, Bethesda, Maryland, USA. Guang Chen, Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Program, NIMH, NIH, Bethesda, Maryland, USA.
A large and growing number of new therapeutic compounds aiming at “disease

modification” Inhibitors,research,lifescience,medical in Alzheimer’s disease (AD) are currently under clinical investigation (Table I). However, these innovative therapeutic approaches require a variety of novel biomarkers with differentiated roles and functions to ensure objectivity and efficiency of drug development, as well as the initiation and monitoring of drug treatment in patients. Accordingly, new guideline documents from regulatory authorities, such as the FDA and EMEA, Inhibitors,research,lifescience,medical will most likely strongly recommend thorough validation of biological, as well as imaging, candidate markers as primary end points in upcoming phase II and III treatment trials of compounds claiming disease-modifying properties. In this context, the ideal biomarker would

serve Inhibitors,research,lifescience,medical at least two purposes. First, it would enable early diagnosis, which also relates to early detection of pathophysiology. This is particularly important for “disease modification” and early intervention in a condition that progresses for 5 to 8 years prior to awareness of cognitive loss. Secondly, the biomarker would enable assessment of objective treatment benefit so that the Dacomitinib therapeutic regimen could be adjusted according to patient response. Those biomarkers could also serve as objective end points in clinical trials assessing the efficacy of new compounds. Table I. Potential disease-modifying and amyloid-targeting agents in development. Sources: a, www.clinicaltrials.gov; b, www.neurochem.com; c, www.lilly.com; d, www.cornell.edu; e, www.phrma.org; f, www.regentherapeutics.com; g, www.affiris.